Allied Market Research
Loading...
0
New
New
2022
Cancer Gene Therapy Market

Cancer Gene Therapy Market by Therapy (Gene Induced Immunotherapy, Oncolytic Virotherapy, Gene Transfer), by End User (Hospitals, Diagnostic centers, Research Institutes): Global Opportunity Analysis and Industry Forecast, 2020-2030

A02273
Pages: 186
Mar 2022 | 14611 Views
   
Author(s) : Vikita Thakur , Onkar Sumant
Tables: 116
Charts: 54
  • Formats*:

  • SIngle User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • It comes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Cancer Gene Therapy Market

Request Now !

Cancer Gene Therapy Market Research, 2030

The global Cancer Gene Therapy Market size was valued at $1.4 billion in 2020 and is projected to reach $11.4 billion by 2030, growing at a CAGR of 23.3% from 2021 to 2030. Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body. Cancer often has the ability to spread throughout your body. It is the second-leading cause of death in the world. Cancer gene therapy is a technique used for the treatment of cancer where therapeutic DNA is being introduced into the gene of the patient with cancer. Owing to the high success rate during the preclinical and clinical trials, cancer gene therapy has gained popularity. There are many techniques used for cancer gene therapy, for example, a procedure where the mutated gene is being replaced with a healthy gene or the inactivation of a gene whose function is abnormal. Recently, a new technique has been developed, where new genes are introduced into the body to help fight against cancer cells.

The COVID-19 pandemic has a negative impact on the cancer gene therapy market. As per the article published in Cancer Connect 2020, doctors from Dana Farber Cancer Institute determined that during the COVID-19 pandemic, there was a 46% decrease in the diagnoses of the six most common cancer types - breast, colorectal, lung, pancreatic, gastric, and oesophageal cancers. Moreover, the Centres for Disease Control and Prevention (CDC) &many medical professional organizations recommended that cancer screening and other health prevention services, along with elective surgeries, be postponed unless the risks outweighed the benefits and secure the hospital infrastructure for the treatment of COVID-19 patients. Thus, the COVID-19 pandemic has impacted the cancer gene therapy market. However, the situation is expected to gradually improve.

 

The key factors that boost the Cancer Gene Therapy Market growth are an increase in funding of R&D in the activities of cancer gene therapy along with the rising in the prevalence of cancer. In addition, the favorable government regulations for therapy are further going to boost various opportunities that are anticipated to provide Cancer Gene Therapy Market opportunity during the forecast period. In addition, the risk of cancer gene therapy is less, as a new gene introduced will integrate itself into the genome of the patient and continue functioning without hampering the operations of other genes are the key factors anticipating the growth of the market in upcoming years.. Hence, these aforementioned factors helps in increasing the global cancer gene therapy share. However, the high cost involved in gene therapy along with unwanted immune responses is likely to hamper the growth of the cancer gene therapy market during the forecast period.

The Gene Therapy Industry is segmented on the basis of therapy, end-user, and region. By therapy, it is categorized into gene-induced immunotherapy, oncolytic virotherapy, and gene transfer. By end-user, it is categorized into hospitals, diagnostic centers, and research institutes. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Therapy Segment Review

Cancer Gene Therapy Market
By Therapy

Your browser does not support the canvas element.

Gene induced immnotherapy segment holds a dominant position in 2020 and would continue to maintain the lead over the forecast period.

By therapy, the cancer gene therapy market is categorized into oncolytic virotherapy, gene transfer, and gene-induced immunotherapy. The gene-induced immunotherapy segment dominates the market owing to the rise in the advancement of gene-induced immunotherapy research, increase in funding for R&D activities pertaining to cancer gene therapy, and rise in awareness regarding cancer gene therapy are the key factors anticipating the growth of the market in upcoming years.

End-User Segment Review

Cancer Gene Therapy Market
By End User

Your browser does not support the canvas element.

Hospitals segment holds a dominant position in 2020 and would continue to maintain the lead over the forecast period.

By end-user, the cancer gene therapy market is categorized into hospitals, diagnostic centers, and research institutes. The hospital segment was the major contributor to the global market in 2020 and is anticipated to remain dominant during the forecast period, due to the increase in healthcare awareness, rise in the number of hospitals, and growth in the geriatric and bariatric populations are the key factors anticipating the growth of the market in upcoming years..

 

Region Segment Review

Cancer Gene Therapy Market
By Region

2030
North America 
Europe
Asia-pacific
Lamea

North America segment holds a dominant position in 2020 and would continue to maintain the lead over the forecast period.

By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America was the highest  Cancer Gene Therapy Market share, with $564.52 million in 2020, and is estimated to reach $4,307.47 million by 2030, registering a CAGR of 22.5% during the forecast period. Owing to significant investments in research and advancements in technology, the Asia-Pacific market is estimated to reach $2,913.67million at a significant CAGR of 24.9%. The presence of a large population base, government initiatives to improve healthcare infrastructure, and an increase in healthcare expenditure are the key driving factors that boost the viral vectors and plasmid DNA market in the region.

The key players that operate in the cancer gene therapy market include Adaptimmune, GlaxoSmithKline, Bluebird bio, Inc., Merck, Celgene, Shanghai Sunway Biotech, BioCancell, Shenzhen SiBionoGeneTech, SynerGene Therapeutics, and OncoGenex Pharmaceuticals.

Other prominent players in the value chain include Genelux Corporation, Cell Genesys, Advantagene, GenVec, BioCancell, Celgene, Epeius Biotechnologies, Introgen Therapeutics, Ziopharm Oncology, Shenzhen SiBionoGeneTech, and Altor Bioscience

Get more information on this report : Request Sample Pages

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the cancer gene therapy market analysis from 2020 to 2030 to identify the prevailing cancer gene therapy market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the cancer gene therapy market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global cancer gene therapy market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

  • By Therapy
    • Gene Induced Immunotherapy
    • Oncolytic Virotherapy
    • Gene Transfer
  • By End User
    • Hospitals
    • Diagnostic centers
    • Research Institutes
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • Germany
      • France
      • U.K.
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • Japan
      • China
      • Australia
      • India
      • South Korea
      • Rest Of Asia Pacific
    • LAMEA
      • Brazil
      • Saudi Arabia
      • South Africa
      • Rest of LAMEA


Key Market Players

  • Bristol Myers Squibb Co.
  • Novartis
  • Amgen Inc.
  • Glaxosmithkline PLC
  • Kayropharma Therapeutics
  • Gilead Sciences
  • Adapta Immue
  • Genulex Corporation
  • SynerGene Therapeutics
  • shanghai sunway biotech
 
  • CHAPTER 1:INTRODUCTION

    • 1.1.Report description

    • 1.2.Key market segments

    • 1.3.Key benefits to the stakeholders

    • 1.4.Research Methodology

      • 1.4.1.Secondary research

      • 1.4.2.Primary research

      • 1.4.3.Analyst tools and models

  • CHAPTER 2:EXECUTIVE SUMMARY

    • 2.1.Key findings of the study

    • 2.2.CXO Perspective

  • CHAPTER 3:MARKET OVERVIEW

    • 3.1.Market definition and scope

    • 3.2.Key findings

      • 3.2.1.Top investment pockets

    • 3.3.Porter’s five forces analysis

    • 3.4.Top player positioning

    • 3.5.Market dynamics

      • 3.5.1.Drivers

      • 3.5.2.Restraints

      • 3.5.3.Opportunities

    • 3.6.COVID-19 Impact Analysis on the market

  • CHAPTER 4: CANCER GENE THERAPY MARKET, BY THERAPY

    • 4.1 Overview

      • 4.1.1 Market size and forecast

    • 4.2 Gene Induced Immunotherapy

      • 4.2.1 Key market trends, growth factors and opportunities

      • 4.2.2 Market size and forecast, by region

      • 4.2.3 Market analysis by country

    • 4.3 Oncolytic Virotherapy

      • 4.3.1 Key market trends, growth factors and opportunities

      • 4.3.2 Market size and forecast, by region

      • 4.3.3 Market analysis by country

    • 4.4 Gene Transfer

      • 4.4.1 Key market trends, growth factors and opportunities

      • 4.4.2 Market size and forecast, by region

      • 4.4.3 Market analysis by country

  • CHAPTER 5: CANCER GENE THERAPY MARKET, BY END USER

    • 5.1 Overview

      • 5.1.1 Market size and forecast

    • 5.2 Hospitals

      • 5.2.1 Key market trends, growth factors and opportunities

      • 5.2.2 Market size and forecast, by region

      • 5.2.3 Market analysis by country

    • 5.3 Diagnostic centers

      • 5.3.1 Key market trends, growth factors and opportunities

      • 5.3.2 Market size and forecast, by region

      • 5.3.3 Market analysis by country

    • 5.4 Research Institutes

      • 5.4.1 Key market trends, growth factors and opportunities

      • 5.4.2 Market size and forecast, by region

      • 5.4.3 Market analysis by country

  • CHAPTER 6: CANCER GENE THERAPY MARKET, BY REGION

    • 6.1 Overview

      • 6.1.1 Market size and forecast

    • 6.2 North America

      • 6.2.1 Key trends and opportunities

      • 6.2.2 North America Market size and forecast, by Therapy

      • 6.2.3 North America Market size and forecast, by End User

      • 6.2.4 North America Market size and forecast, by country

        • 6.2.4.1 U.S.
          • 6.2.4.1.1 Market size and forecast, by Therapy
          • 6.2.4.1.2 Market size and forecast, by End User
        • 6.2.4.2 Canada
          • 6.2.4.2.1 Market size and forecast, by Therapy
          • 6.2.4.2.2 Market size and forecast, by End User
        • 6.2.4.3 Mexico
          • 6.2.4.3.1 Market size and forecast, by Therapy
          • 6.2.4.3.2 Market size and forecast, by End User
    • 6.3 Europe

      • 6.3.1 Key trends and opportunities

      • 6.3.2 Europe Market size and forecast, by Therapy

      • 6.3.3 Europe Market size and forecast, by End User

      • 6.3.4 Europe Market size and forecast, by country

        • 6.3.4.1 Germany
          • 6.3.4.1.1 Market size and forecast, by Therapy
          • 6.3.4.1.2 Market size and forecast, by End User
        • 6.3.4.2 France
          • 6.3.4.2.1 Market size and forecast, by Therapy
          • 6.3.4.2.2 Market size and forecast, by End User
        • 6.3.4.3 U.K.
          • 6.3.4.3.1 Market size and forecast, by Therapy
          • 6.3.4.3.2 Market size and forecast, by End User
        • 6.3.4.4 Italy
          • 6.3.4.4.1 Market size and forecast, by Therapy
          • 6.3.4.4.2 Market size and forecast, by End User
        • 6.3.4.5 Spain
          • 6.3.4.5.1 Market size and forecast, by Therapy
          • 6.3.4.5.2 Market size and forecast, by End User
        • 6.3.4.6 Rest of Europe
          • 6.3.4.6.1 Market size and forecast, by Therapy
          • 6.3.4.6.2 Market size and forecast, by End User
    • 6.4 Asia-Pacific

      • 6.4.1 Key trends and opportunities

      • 6.4.2 Asia-Pacific Market size and forecast, by Therapy

      • 6.4.3 Asia-Pacific Market size and forecast, by End User

      • 6.4.4 Asia-Pacific Market size and forecast, by country

        • 6.4.4.1 Japan
          • 6.4.4.1.1 Market size and forecast, by Therapy
          • 6.4.4.1.2 Market size and forecast, by End User
        • 6.4.4.2 China
          • 6.4.4.2.1 Market size and forecast, by Therapy
          • 6.4.4.2.2 Market size and forecast, by End User
        • 6.4.4.3 Australia
          • 6.4.4.3.1 Market size and forecast, by Therapy
          • 6.4.4.3.2 Market size and forecast, by End User
        • 6.4.4.4 India
          • 6.4.4.4.1 Market size and forecast, by Therapy
          • 6.4.4.4.2 Market size and forecast, by End User
        • 6.4.4.5 South Korea
          • 6.4.4.5.1 Market size and forecast, by Therapy
          • 6.4.4.5.2 Market size and forecast, by End User
        • 6.4.4.6 Rest Of Asia Pacific
          • 6.4.4.6.1 Market size and forecast, by Therapy
          • 6.4.4.6.2 Market size and forecast, by End User
    • 6.5 LAMEA

      • 6.5.1 Key trends and opportunities

      • 6.5.2 LAMEA Market size and forecast, by Therapy

      • 6.5.3 LAMEA Market size and forecast, by End User

      • 6.5.4 LAMEA Market size and forecast, by country

        • 6.5.4.1 Brazil
          • 6.5.4.1.1 Market size and forecast, by Therapy
          • 6.5.4.1.2 Market size and forecast, by End User
        • 6.5.4.2 Saudi Arabia
          • 6.5.4.2.1 Market size and forecast, by Therapy
          • 6.5.4.2.2 Market size and forecast, by End User
        • 6.5.4.3 South Africa
          • 6.5.4.3.1 Market size and forecast, by Therapy
          • 6.5.4.3.2 Market size and forecast, by End User
        • 6.5.4.4 Rest of LAMEA
          • 6.5.4.4.1 Market size and forecast, by Therapy
          • 6.5.4.4.2 Market size and forecast, by End User
  • CHAPTER 7: COMPANY LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top winning strategies

    • 7.3. Product Mapping of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Key developments

  • CHAPTER 8: COMPANY PROFILES

    • 8.1 Bristol Myers Squibb Co.

      • 8.1.1 Company overview

      • 8.1.2 Company snapshot

      • 8.1.3 Operating business segments

      • 8.1.4 Product portfolio

      • 8.1.5 Business performance

      • 8.1.6 Key strategic moves and developments

    • 8.2 Novartis

      • 8.2.1 Company overview

      • 8.2.2 Company snapshot

      • 8.2.3 Operating business segments

      • 8.2.4 Product portfolio

      • 8.2.5 Business performance

      • 8.2.6 Key strategic moves and developments

    • 8.3 Amgen Inc.

      • 8.3.1 Company overview

      • 8.3.2 Company snapshot

      • 8.3.3 Operating business segments

      • 8.3.4 Product portfolio

      • 8.3.5 Business performance

      • 8.3.6 Key strategic moves and developments

    • 8.4 Glaxosmithkline PLC

      • 8.4.1 Company overview

      • 8.4.2 Company snapshot

      • 8.4.3 Operating business segments

      • 8.4.4 Product portfolio

      • 8.4.5 Business performance

      • 8.4.6 Key strategic moves and developments

    • 8.5 Kayropharma Therapeutics

      • 8.5.1 Company overview

      • 8.5.2 Company snapshot

      • 8.5.3 Operating business segments

      • 8.5.4 Product portfolio

      • 8.5.5 Business performance

      • 8.5.6 Key strategic moves and developments

    • 8.6 Gilead Sciences

      • 8.6.1 Company overview

      • 8.6.2 Company snapshot

      • 8.6.3 Operating business segments

      • 8.6.4 Product portfolio

      • 8.6.5 Business performance

      • 8.6.6 Key strategic moves and developments

    • 8.7 Adapta Immue

      • 8.7.1 Company overview

      • 8.7.2 Company snapshot

      • 8.7.3 Operating business segments

      • 8.7.4 Product portfolio

      • 8.7.5 Business performance

      • 8.7.6 Key strategic moves and developments

    • 8.8 Genulex Corporation

      • 8.8.1 Company overview

      • 8.8.2 Company snapshot

      • 8.8.3 Operating business segments

      • 8.8.4 Product portfolio

      • 8.8.5 Business performance

      • 8.8.6 Key strategic moves and developments

    • 8.9 SynerGene Therapeutics

      • 8.9.1 Company overview

      • 8.9.2 Company snapshot

      • 8.9.3 Operating business segments

      • 8.9.4 Product portfolio

      • 8.9.5 Business performance

      • 8.9.6 Key strategic moves and developments

    • 8.10 shanghai sunway biotech

      • 8.10.1 Company overview

      • 8.10.2 Company snapshot

      • 8.10.3 Operating business segments

      • 8.10.4 Product portfolio

      • 8.10.5 Business performance

      • 8.10.6 Key strategic moves and developments

    Note: Details on financial performance and strategic moves and developments may not be captured for unlisted companies.

  • LIST OF TABLES

  • TABLE 1. GLOBAL CANCER GENE THERAPY MARKET, BY THERAPY, 2020-2030,($MILLION)
    TABLE 2. CANCER GENE THERAPY MARKET REVENUE, FOR GENE INDUCED IMMUNOTHERAPY, BY REGION , 2020-2030,($MILLION)
    TABLE 3. CANCER GENE THERAPY MARKET GENE INDUCED IMMUNOTHERAPY BY COUNTRY, 2020-2030,($MILLION)
    TABLE 4. CANCER GENE THERAPY MARKET REVENUE, FOR ONCOLYTIC VIROTHERAPY, BY REGION , 2020-2030,($MILLION)
    TABLE 5. CANCER GENE THERAPY MARKET ONCOLYTIC VIROTHERAPY BY COUNTRY, 2020-2030,($MILLION)
    TABLE 6. CANCER GENE THERAPY MARKET REVENUE, FOR GENE TRANSFER, BY REGION , 2020-2030,($MILLION)
    TABLE 7. CANCER GENE THERAPY MARKET GENE TRANSFER BY COUNTRY, 2020-2030,($MILLION)
    TABLE 8. GLOBAL CANCER GENE THERAPY MARKET, BY END USER, 2020-2030,($MILLION)
    TABLE 9. CANCER GENE THERAPY MARKET REVENUE, FOR HOSPITALS, BY REGION , 2020-2030,($MILLION)
    TABLE 10. CANCER GENE THERAPY MARKET HOSPITALS BY COUNTRY, 2020-2030,($MILLION)
    TABLE 11. CANCER GENE THERAPY MARKET REVENUE, FOR DIAGNOSTIC CENTERS, BY REGION , 2020-2030,($MILLION)
    TABLE 12. CANCER GENE THERAPY MARKET DIAGNOSTIC CENTERS BY COUNTRY, 2020-2030,($MILLION)
    TABLE 13. CANCER GENE THERAPY MARKET REVENUE, FOR RESEARCH INSTITUTES, BY REGION , 2020-2030,($MILLION)
    TABLE 14. CANCER GENE THERAPY MARKET RESEARCH INSTITUTES BY COUNTRY, 2020-2030,($MILLION)
    TABLE 15. CANCER GENE THERAPY MARKET, BY REGION, 2020-2030,($MILLION)
    TABLE 16. NORTH AMERICA CANCER GENE THERAPY MARKET, BY THERAPY, 2020-2030,($MILLION)
    TABLE 17. NORTH AMERICA CANCER GENE THERAPY MARKET, BY END USER, 2020-2030,($MILLION)
    TABLE 18. NORTH AMERICA CANCER GENE THERAPY MARKET, BY COUNTRY, 2020-2030,($MILLION)
    TABLE 19. U.S. CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
    TABLE 20. U.S. CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
    TABLE 21. CANADA CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
    TABLE 22. CANADA CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
    TABLE 23. MEXICO CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
    TABLE 24. MEXICO CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
    TABLE 25. EUROPE CANCER GENE THERAPY MARKET, BY THERAPY, 2020-2030,($MILLION)
    TABLE 26. EUROPE CANCER GENE THERAPY MARKET, BY END USER, 2020-2030,($MILLION)
    TABLE 27. EUROPE CANCER GENE THERAPY MARKET, BY COUNTRY, 2020-2030,($MILLION)
    TABLE 28. GERMANY CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
    TABLE 29. GERMANY CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
    TABLE 30. FRANCE CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
    TABLE 31. FRANCE CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
    TABLE 32. U.K. CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
    TABLE 33. U.K. CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
    TABLE 34. ITALY CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
    TABLE 35. ITALY CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
    TABLE 36. SPAIN CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
    TABLE 37. SPAIN CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
    TABLE 38. REST OF EUROPE CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
    TABLE 39. REST OF EUROPE CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
    TABLE 40. ASIA-PACIFIC CANCER GENE THERAPY MARKET, BY THERAPY, 2020-2030,($MILLION)
    TABLE 41. ASIA-PACIFIC CANCER GENE THERAPY MARKET, BY END USER, 2020-2030,($MILLION)
    TABLE 42. ASIA-PACIFIC CANCER GENE THERAPY MARKET, BY COUNTRY, 2020-2030,($MILLION)
    TABLE 43. JAPAN CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
    TABLE 44. JAPAN CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
    TABLE 45. CHINA CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
    TABLE 46. CHINA CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
    TABLE 47. AUSTRALIA CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
    TABLE 48. AUSTRALIA CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
    TABLE 49. INDIA CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
    TABLE 50. INDIA CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
    TABLE 51. SOUTH KOREA CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
    TABLE 52. SOUTH KOREA CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
    TABLE 53. REST OF ASIA PACIFIC CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
    TABLE 54. REST OF ASIA PACIFIC CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
    TABLE 55. LAMEA CANCER GENE THERAPY MARKET, BY THERAPY, 2020-2030,($MILLION)
    TABLE 56. LAMEA CANCER GENE THERAPY MARKET, BY END USER, 2020-2030,($MILLION)
    TABLE 57. LAMEA CANCER GENE THERAPY MARKET, BY COUNTRY, 2020-2030,($MILLION)
    TABLE 58. BRAZIL CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
    TABLE 59. BRAZIL CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
    TABLE 60. SAUDI ARABIA CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
    TABLE 61. SAUDI ARABIA CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
    TABLE 62. SOUTH AFRICA CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
    TABLE 63. SOUTH AFRICA CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
    TABLE 64. REST OF LAMEA CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
    TABLE 65. REST OF LAMEA CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
    TABLE 66.BRISTOL MYERS SQUIBB CO.: COMPANY SNAPSHOT
    TABLE 67.BRISTOL MYERS SQUIBB CO.: OPERATING SEGMENTS
    TABLE 68.BRISTOL MYERS SQUIBB CO.: PRODUCT PORTFOLIO
    TABLE 69.BRISTOL MYERS SQUIBB CO.: NET SALES,
    TABLE 70.BRISTOL MYERS SQUIBB CO.: KEY STRATERGIES
    TABLE 71.NOVARTIS: COMPANY SNAPSHOT
    TABLE 72.NOVARTIS: OPERATING SEGMENTS
    TABLE 73.NOVARTIS: PRODUCT PORTFOLIO
    TABLE 74.NOVARTIS: NET SALES,
    TABLE 75.NOVARTIS: KEY STRATERGIES
    TABLE 76.AMGEN INC.: COMPANY SNAPSHOT
    TABLE 77.AMGEN INC.: OPERATING SEGMENTS
    TABLE 78.AMGEN INC.: PRODUCT PORTFOLIO
    TABLE 79.AMGEN INC.: NET SALES,
    TABLE 80.AMGEN INC.: KEY STRATERGIES
    TABLE 81.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
    TABLE 82.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
    TABLE 83.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
    TABLE 84.GLAXOSMITHKLINE PLC: NET SALES,
    TABLE 85.GLAXOSMITHKLINE PLC: KEY STRATERGIES
    TABLE 86.KAYROPHARMA THERAPEUTICS: COMPANY SNAPSHOT
    TABLE 87.KAYROPHARMA THERAPEUTICS: OPERATING SEGMENTS
    TABLE 88.KAYROPHARMA THERAPEUTICS: PRODUCT PORTFOLIO
    TABLE 89.KAYROPHARMA THERAPEUTICS: NET SALES,
    TABLE 90.KAYROPHARMA THERAPEUTICS: KEY STRATERGIES
    TABLE 91.GILEAD SCIENCES: COMPANY SNAPSHOT
    TABLE 92.GILEAD SCIENCES: OPERATING SEGMENTS
    TABLE 93.GILEAD SCIENCES: PRODUCT PORTFOLIO
    TABLE 94.GILEAD SCIENCES: NET SALES,
    TABLE 95.GILEAD SCIENCES: KEY STRATERGIES
    TABLE 96.ADAPTA IMMUE: COMPANY SNAPSHOT
    TABLE 97.ADAPTA IMMUE: OPERATING SEGMENTS
    TABLE 98.ADAPTA IMMUE: PRODUCT PORTFOLIO
    TABLE 99.ADAPTA IMMUE: NET SALES,
    TABLE 100.ADAPTA IMMUE: KEY STRATERGIES
    TABLE 101.GENULEX CORPORATION: COMPANY SNAPSHOT
    TABLE 102.GENULEX CORPORATION: OPERATING SEGMENTS
    TABLE 103.GENULEX CORPORATION: PRODUCT PORTFOLIO
    TABLE 104.GENULEX CORPORATION: NET SALES,
    TABLE 105.GENULEX CORPORATION: KEY STRATERGIES
    TABLE 106.SYNERGENE THERAPEUTICS: COMPANY SNAPSHOT
    TABLE 107.SYNERGENE THERAPEUTICS: OPERATING SEGMENTS
    TABLE 108.SYNERGENE THERAPEUTICS: PRODUCT PORTFOLIO
    TABLE 109.SYNERGENE THERAPEUTICS: NET SALES,
    TABLE 110.SYNERGENE THERAPEUTICS: KEY STRATERGIES
    TABLE 111.SHANGHAI SUNWAY BIOTECH: COMPANY SNAPSHOT
    TABLE 112.SHANGHAI SUNWAY BIOTECH: OPERATING SEGMENTS
    TABLE 113.SHANGHAI SUNWAY BIOTECH: PRODUCT PORTFOLIO
    TABLE 114.SHANGHAI SUNWAY BIOTECH: NET SALES,
    TABLE 115.SHANGHAI SUNWAY BIOTECH: KEY STRATERGIES
  • LIST OF FIGURES

  • FIGURE 1.CANCER GENE THERAPY MARKET SEGMENTATION
    FIGURE 2.CANCER GENE THERAPY MARKET,2020-2030
    FIGURE 3.CANCER GENE THERAPY MARKET,2020-2030
    FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
    FIGURE 5.PORTER FIVE-1
    FIGURE 6.PORTER FIVE-2
    FIGURE 7.PORTER FIVE-3
    FIGURE 8.PORTER FIVE-4
    FIGURE 9.PORTER FIVE-5
    FIGURE 10.TOP PLAYER POSITIONING
    FIGURE 11.CANCER GENE THERAPY MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
    FIGURE 11.CANCER GENE THERAPY MARKET,BY THERAPY,2020(%)
    FIGURE 12.COMPARATIVE SHARE ANALYSIS OF GENE INDUCED IMMUNOTHERAPY CANCER GENE THERAPY MARKET,2020-2030(%)
    FIGURE 13.COMPARATIVE SHARE ANALYSIS OF ONCOLYTIC VIROTHERAPY CANCER GENE THERAPY MARKET,2020-2030(%)
    FIGURE 14.COMPARATIVE SHARE ANALYSIS OF GENE TRANSFER CANCER GENE THERAPY MARKET,2020-2030(%)
    FIGURE 15.CANCER GENE THERAPY MARKET,BY END USER,2020(%)
    FIGURE 16.COMPARATIVE SHARE ANALYSIS OF HOSPITALS CANCER GENE THERAPY MARKET,2020-2030(%)
    FIGURE 17.COMPARATIVE SHARE ANALYSIS OF DIAGNOSTIC CENTERS CANCER GENE THERAPY MARKET,2020-2030(%)
    FIGURE 18.COMPARATIVE SHARE ANALYSIS OF RESEARCH INSTITUTES CANCER GENE THERAPY MARKET,2020-2030(%)
    FIGURE 19.CANCER GENE THERAPY MARKET BY REGION,2020
    FIGURE 20.U.S. CANCER GENE THERAPY MARKET,2020-2030($MILLION)
    FIGURE 21.CANADA CANCER GENE THERAPY MARKET,2020-2030($MILLION)
    FIGURE 22.MEXICO CANCER GENE THERAPY MARKET,2020-2030($MILLION)
    FIGURE 23.GERMANY CANCER GENE THERAPY MARKET,2020-2030($MILLION)
    FIGURE 24.FRANCE CANCER GENE THERAPY MARKET,2020-2030($MILLION)
    FIGURE 25.U.K. CANCER GENE THERAPY MARKET,2020-2030($MILLION)
    FIGURE 26.ITALY CANCER GENE THERAPY MARKET,2020-2030($MILLION)
    FIGURE 27.SPAIN CANCER GENE THERAPY MARKET,2020-2030($MILLION)
    FIGURE 28.REST OF EUROPE CANCER GENE THERAPY MARKET,2020-2030($MILLION)
    FIGURE 29.JAPAN CANCER GENE THERAPY MARKET,2020-2030($MILLION)
    FIGURE 30.CHINA CANCER GENE THERAPY MARKET,2020-2030($MILLION)
    FIGURE 31.AUSTRALIA CANCER GENE THERAPY MARKET,2020-2030($MILLION)
    FIGURE 32.INDIA CANCER GENE THERAPY MARKET,2020-2030($MILLION)
    FIGURE 33.SOUTH KOREA CANCER GENE THERAPY MARKET,2020-2030($MILLION)
    FIGURE 34.REST OF ASIA PACIFIC CANCER GENE THERAPY MARKET,2020-2030($MILLION)
    FIGURE 35.BRAZIL CANCER GENE THERAPY MARKET,2020-2030($MILLION)
    FIGURE 36.SAUDI ARABIA CANCER GENE THERAPY MARKET,2020-2030($MILLION)
    FIGURE 37.SOUTH AFRICA CANCER GENE THERAPY MARKET,2020-2030($MILLION)
    FIGURE 38.REST OF LAMEA CANCER GENE THERAPY MARKET,2020-2030($MILLION)
    FIGURE 39. TOP WINNING STRATEGIES, BY YEAR
    FIGURE 40. TOP WINNING STRATEGIES, BY DEVELOPMENT
    FIGURE 41. TOP WINNING STRATEGIES, BY COMPANY
    FIGURE 42.PRODUCT MAPPING OF TOP 10 PLAYERS
    FIGURE 43.COMPETITIVE DASHBOARD
    FIGURE 44.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
    FIGURE 45.BRISTOL MYERS SQUIBB CO..: NET SALES ,($MILLION)
    FIGURE 46.NOVARTIS.: NET SALES ,($MILLION)
    FIGURE 47.AMGEN INC..: NET SALES ,($MILLION)
    FIGURE 48.GLAXOSMITHKLINE PLC.: NET SALES ,($MILLION)
    FIGURE 49.KAYROPHARMA THERAPEUTICS.: NET SALES ,($MILLION)
    FIGURE 50.GILEAD SCIENCES.: NET SALES ,($MILLION)
    FIGURE 51.ADAPTA IMMUE.: NET SALES ,($MILLION)
    FIGURE 52.GENULEX CORPORATION.: NET SALES ,($MILLION)
    FIGURE 53.SYNERGENE THERAPEUTICS.: NET SALES ,($MILLION)
    FIGURE 54.SHANGHAI SUNWAY BIOTECH.: NET SALES ,($MILLION)

 
 

According to CXOs, the demand for cancer gene therapy has increased rapidly. The rise in the prevalence of cancer and increase in biotechnological funding that encourage the R&D activities for cancer gene therapy are the major factors that drive the market growth. In addition, the benefits of cancer gene therapy over conventional cancer therapies and an increase in government support fuel the growth of the cancer gene therapy market. Furthermore, ethical acceptance of gene therapy for cancer treatment, short-duration treatment, and the advancement in this field boost the market growth. However, the high cost associated with the treatment and unwanted immune responses is expected to restrain the market.

Gene transfer therapy is expected to be a lucrative segment for the market players as it is the fastest-growing segment. The therapy involves the introduction of new genes into the tumor cells. It is an emerging cancer treatment method and seems to show positive results in preclinical and clinical studies.

The employment of cancer gene therapy is highest in North America, owing to a rise in funding for R&D activities, the high prevalence rate of cancer, and a surge in disposable income among customers. Although the use of cancer gene therapy in the Asia-Pacific and LAMEA region is low, the adoption rate is expected to increase due to a rise in disposable income, the surge in the incidence rate of cancer, and government initiatives to improve healthcare infrastructure, which in turn fuel the market growth.

PURCHASE OPTIONS

Start reading instantly ,This Report and over 13000+ thousand more Reports, Available with Avenue Library, T&C*

Call or Email us

U.S.-Canada
Toll-free :
+1-800-792-5285
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email : help@alliedmarketresearch.com
FREQUENTLY ASKED QUESTIONS?
Our Report Looks Like This
 

A. The top companies to hold the market share in Cancer Gene Therapy are Adaptimmune, GlaxoSmithKline, Bluebird bio, Inc., Merck, Celgene, Shanghai Sunway Biotech, BioCancell, Shenzhen SiBionoGeneTech, SynerGene Therapeutics, and OncoGenex Pharmaceuticals.

A. North America largest regional market for Cancer Gene Therapy.

A. The upcoming trends of the Cancer Gene Therapy Market in the world are an increase in funding of R&D in the activities of cancer gene therapy along with rise in prevalence of cancer. In addition, the favourable government regulations for therapy are further going to boost various opportunities that are anticipated to lead to the growth of the cancer gene therapy market during the forecast period.

A. The total market value of the Cancer Gene Therapy Market is $11,359.35 million by 2030.

A. No, there is no value chain analysis provided in the Cancer Gene Therapy Market report

A. The global Cancer Gene Therapy market was valued at $1,389.42 million in 2020

Allied Market Research Allied Market Research Allied Market Research
RELATED TAGS
 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Cancer Gene Therapy Market

Start reading instantly.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,217
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,574
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,398
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,004
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $9,373
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Erythropoietin Drugs Market

Global Opportunity Analysis and Industry Forecast, 2021–2028

Published in May 2021

Download Sample

Protein Therapeutics Market

Global Opportunity Analysis and Industry Forecast, 2021–2030

Published in Feb 2022

Download Sample

Surgical Equipment Market

Global Opportunity Analysis and Industry Forecast, 2020-2027

Published in Jan 2021

Download Sample

Medical Implant Market

Global Opportunity Analysis and Industry Forecast, 2020–2027

Published in Nov 2020

Download Sample

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers